Abstract: The T-type three-level inverters have enormous promise in medium-voltage drives for aircraft electric-propulsion applications. The phase-shifted carrier-based pulsewidth modulation (CBPWM) ...

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for ...

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that the ...

COLUMBUS, Ohio — The effort to draw new boundaries for Ohio's 15 U.S. congressional districts officially moved into phase two Tuesday morning when the Ohio Redistricting Commission held its first ...

Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC. Data from the phase 3 PSMAddition trial (NCT04720157) ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...

The biggest stories of the day delivered to your inbox.

Abstract: This paper proposes input current ripple analysis of three phase inverter with de-link referenced output filter, known as three phase modified buck-boost inverter. The filter consists of an ...

Nearly all children with spinal muscular atrophy (SMA) who were started early on Evrysdi (risdiplam) in a clinical trial — as newborns, before the onset of symptoms — are now walking after three years ...

Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now it can celebrate a key trial win for its first drug to gain an FDA approval in ...

Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee — Global Trial to Assess Injectable Biologic Therapy for Pain ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...